DDL, a provider of package, product, and material testing services, announced on Monday the opening of a new Good Manufacturing Practice (GMP) laboratory for drug-device combination product testing.
This expansion enhances DDL's capacity to support the pharmaceutical, biotech and combination product industries with rigorous, regulatory-compliant testing solutions.
The new FDA-registered 10,600 sq ft GMP lab is located near DDL's headquarters in Eden Prairie, Minnesota. The lab will offer ICH stability testing, functional and mechanical performance testing (ISO 11040 & ISO 11608) and simulated distribution testing to meet the growing demand for high-quality GMP testing for devices such as auto injectors, pre-filled syringes, inhalers and other combination products.
DDL said that its new facility will provide comprehensive testing solutions in accordance with FDA, ISO and other global regulatory standards.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval